http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210075211-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27b8aed7eadea74815c22872a8bd7366
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
filingDate 2014-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe5b31252310f87eb5de02305a884ecb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81feff7f89c0dede108fe0f18d3a3533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c476ee16792b64ea0ff571f12a0fa616
publicationDate 2021-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber KR-20210075211-A
titleOfInvention Pharmaceutical formulations for subcutaneous administration of furosemide
abstract The teachings of the present invention are directed to liquid pharmaceutical formulations of furosemide, wherein the pharmaceutical formulation comprises a molar excess of tris(hydroxymethyl)aminomethane with respect to furosemide, and a pH in the range of 7 to 8.5 and about 50 having a tris(hydroxymethyl)aminomethane concentration of at least mM. The teachings of the present invention may improve the stability of liquid pharmaceutical formulations comprising furosemide, and suitability for subcutaneous administration or delivery of such pharmaceutical formulations.
priorityDate 2013-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4861786-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4698361-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID93573
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448492419
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419484275
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419526964
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3777159
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID516892
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3440
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419533897
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23673593
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453034310
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6503
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452088256

Total number of triples: 38.